Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$100,000.00

Targeting the cellular origins of PIK3CA mutant breast cancer with imaging mass cytometry

EF 2015-16

Résumé
Breast cancer is classified into subtypes that vary by their aggressiveness and response to therapy. Surprisingly, the same initiating mutation causes diverse breast cancer subtypes to develop based on the cell from which they originate. Currently, to determine subtype and patient risk, breast tumours are only tested for individual cell markers, one at a time. In this proposal, a novel imaging modality of Canadian mass cytometry technology will be used to simultaneously quantify 40 markers and their correlations within each single cell of a tumour sample. Combinations of markers will be used to define the cell of origin and cell types that make up the different tumour subtypes that are caused by the most common breast cancer causing mutation PIK3CAH1047R. With specific cells of origin identified, multi-parameter mass cytometry measurements will define the communication networks that determine differences in tumour aggressiveness between these subtypes. Computational modeling of intra-cell communication will identify fragile targets for perturbation in each subtype and the impact of specific interventions will be tested on tumour growth. In parallel, these cell markers will be measured in banked breast cancer samples with known patient outcome in order to identify markers, cell populations and new cancer subtypes that correlate with improved patient survival or response to current or new therapies. Working with academic leaders in the field of big-data, systems biology in Switzerland and cutting-edge technology industry experts in Canada, this project will quantify the cellular origins of breast cancer and identify actionable features of aggressive cancer subtypes. Stratifying patient risk according to single cell marks will provide detailed, personalized risk assessments and link breast cancer subtypes to current and future therapies.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Switzerland
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
338639
Name
Jackson Hartland W
Country
Switzerland
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Targeting the cellular origins of PIK3CA mutant breast cancer with imaging mass cytometry
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Breast Cancer; Clinical Markers; Imaging Mass Cytometry; Mouse Models Of Breast Cancer; Patient Diagnosis And Risk Assessment; Single Cell Analysis; Systems Biology; Tumour Heterogeneity
Abstract
Breast cancer is classified into subtypes that vary by their aggressiveness and response to therapy. Surprisingly, the same initiating mutation causes diverse breast cancer subtypes to develop based on the cell from which they originate. Currently, to determine subtype and patient risk, breast tumours are only tested for individual cell markers, one at a time. In this proposal, a novel imaging modality of Canadian mass cytometry technology will be used to simultaneously quantify 40 markers and their correlations within each single cell of a tumour sample. Combinations of markers will be used to define the cell of origin and cell types that make up the different tumour subtypes that are caused by the most common breast cancer causing mutation PIK3CAH1047R. With specific cells of origin identified, multi-parameter mass cytometry measurements will define the communication networks that determine differences in tumour aggressiveness between these subtypes. Computational modeling of intra-cell communication will identify fragile targets for perturbation in each subtype and the impact of specific interventions will be tested on tumour growth. In parallel, these cell markers will be measured in banked breast cancer samples with known patient outcome in order to identify markers, cell populations and new cancer subtypes that correlate with improved patient survival or response to current or new therapies. Working with academic leaders in the field of big-data, systems biology in Switzerland and cutting-edge technology industry experts in Canada, this project will quantify the cellular origins of breast cancer and identify actionable features of aggressive cancer subtypes. Stratifying patient risk according to single cell marks will provide detailed, personalized risk assessments and link breast cancer subtypes to current and future therapies.
Competitiondate
201511
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Jackson, Hartland W
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~